ResearcherJiangsu UniversityActive in the last 2 years
Siqi Zhou
Matched on ORCID iD 0000-0002-0668-340X; OpenAlex author ID A5038003812. Sources: OpenAlex.
Their work
- Papers
- 6
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 17
2019: 1 paper · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: 2 papers
Papers 6
- HHLA2 deficiency inhibits pancreatic cancer progression and THP-1 macrophage M2 polarization via EGFR/MAPK/ERK and mTOR/AKT pathway. Co-author DOI 10.1186/s12957-024-03409-2↗
- Integrated bioinformatics analysis identifies PCSK9 as a prognosticator correlated with lipid metabolism in pancreatic adenocarcinoma. Co-author DOI 10.1186/s12957-024-03532-0↗
- Pirfenidone-loaded exosomes derived from pancreatic ductal adenocarcinoma cells alleviate fibrosis of premetastatic niches to inhibit liver metastasis. Co-author DOI 10.1039/d2bm00770c↗
- Endoscopic Ultrasound-Guided Acquisition of Portal Venous Circulating Tumor Cells as a Potential Diagnostic and Prognostic Tool for Pancreatic Cancer. Co-author DOI 10.2147/cmar.s330473↗
- Plasma-Derived Exosomal ALIX as a Novel Biomarker for Diagnosis and Classification of Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.628346↗
- Genome-wide association study using diversity outcross mice identified candidate genes of pancreatic cancer. Co-author DOI 10.1016/j.ygeno.2018.12.011↗
Closest collaborators
The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Xiaoping Zou · 5 shared papers, 2021–2024 · strength 0.88
- Paper Integrated bioinformatics analysis identifies PCSK9 as a prognosticator correlated with lipid metabolism in pancreatic … DOI 10.1186/s12957-024-03532-0↗
- Paper HHLA2 deficiency inhibits pancreatic cancer progression and THP-1 macrophage M2 polarization via EGFR/MAPK/ERK and mTOR… DOI 10.1186/s12957-024-03409-2↗
- Paper Pirfenidone-loaded exosomes derived from pancreatic ductal adenocarcinoma cells alleviate fibrosis of premetastatic nic… DOI 10.1039/d2bm00770c↗
- Shu Zhang · 3 shared papers, 2021–2024 · strength 0.48
- Paper HHLA2 deficiency inhibits pancreatic cancer progression and THP-1 macrophage M2 polarization via EGFR/MAPK/ERK and mTOR… DOI 10.1186/s12957-024-03409-2↗
- Paper Pirfenidone-loaded exosomes derived from pancreatic ductal adenocarcinoma cells alleviate fibrosis of premetastatic nic… DOI 10.1039/d2bm00770c↗
- Paper Plasma-Derived Exosomal ALIX as a Novel Biomarker for Diagnosis and Classification of Pancreatic Cancer. DOI 10.3389/fonc.2021.628346↗
- Yixuan Zhang · 3 shared papers, 2021–2022 · strength 0.36
- Paper Pirfenidone-loaded exosomes derived from pancreatic ductal adenocarcinoma cells alleviate fibrosis of premetastatic nic… DOI 10.1039/d2bm00770c↗
- Paper Endoscopic Ultrasound-Guided Acquisition of Portal Venous Circulating Tumor Cells as a Potential Diagnostic and Prognos… DOI 10.2147/cmar.s330473↗
- Paper Plasma-Derived Exosomal ALIX as a Novel Biomarker for Diagnosis and Classification of Pancreatic Cancer. DOI 10.3389/fonc.2021.628346↗
- Aotian Chen · 1 shared paper, 2024 · strength 0.28
- Shanshan Shen · 2 shared papers, 2021–2022 · strength 0.25
- Paper Pirfenidone-loaded exosomes derived from pancreatic ductal adenocarcinoma cells alleviate fibrosis of premetastatic nic… DOI 10.1039/d2bm00770c↗
- Paper Endoscopic Ultrasound-Guided Acquisition of Portal Venous Circulating Tumor Cells as a Potential Diagnostic and Prognos… DOI 10.2147/cmar.s330473↗
- Ying Lv · 2 shared papers, 2021–2022 · strength 0.24
- Lei Wang · 1 shared paper, 2022 · strength 0.13
- Jing Zhao · 1 shared paper, 2022 · strength 0.13
- Jing Zhao · 1 shared paper, 2021 · strength 0.12
- Lei Wang · 1 shared paper, 2021 · strength 0.12
- Ying Lv · 1 shared paper, 2021 · strength 0.12
- Hui Wang · 1 shared paper, 2021 · strength 0.11
- Dongming Zhu · 1 shared paper, 2021 · strength 0.11
- Jie An Yang · 1 shared paper, 2021 · strength 0.11
- Xin Gao · 1 shared paper, 2021 · strength 0.11
- Chuanjia Yang · 1 shared paper, 2019 · strength 0.11
- Dongxu Cui · 1 shared paper, 2019 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.